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ABSTRACT
Bone metastasis is the major deleterious event in prostate cancer (PCa). 
TMPRSS2-ERG fusion is one of the most common chromosomic rearrangements in PCa. 
However, its implication in bone metastasis development is still unclear. Since bone 
metastasis starts with the tropism of cancer cells to bone through specific migratory 
and invasive processes involving osteomimetic capabilities, it is crucial to better 
our understanding of the influence of TMPRSS2-ERG expression in the mechanisms 
underlying the bone tropism properties of PCa cells. We developed bioluminescent 
cell lines expressing the TMPRSS2-ERG fusion in order to assess its role in tumor 
growth and bone metastasis appearance in a mouse model. First, we showed that the 
TMPRSS2-ERG fusion increases cell migration and subcutaneous tumor size. Second, 
using intracardiac injection experiments in mice, we showed that the expression 
of TMPRSS2-ERG fusion increases the number of metastases in bone. Moreover, 
TMPRSS2-ERG affects the pattern of metastatic spread by increasing the incidence of 
tumors in hind limbs and spine, which are two of the most frequent sites of human PCa 
metastases. Finally, transcriptome analysis highlighted a series of genes regulated 
by the fusion and involved in the metastatic process. Altogether, our work indicates 
that TMPRSS2-ERG increases bone tropism of PCa cells and metastasis development.
INTRODUCTION
Prostate cancer (PCa) is one of the most commonly 
diagnosed disease and the second cause of cancer-
related deaths affecting men in Western world [1]. Bone 
metastases affect more than 80% of advanced stage PCa 
patients and constitute the major injurious events [2] with 
severe pain, nerve compression and pathologic fracture. 
PCa that has metastasized to bone remains incurable and 
more likely to lead to a fatal outcome than a primary 
tumor. Metastatic prostate cancer cells acquire a bone cell-
like phenotype by a process called osteomimicry, which 
allows their survival and their proliferation in the bone 
marrow microenvironment [3, 4]. At this stage, the tightly-
controlled balance between osteoblastic bone formation and 
osteoclastic bone resorption is aberrantly modified, thereby 
altering bone metabolism [5–7]. Contrary to osteolytic 
lesions observed in breast cancers, PCa bone metastases are 
mainly osteoblastic or mixed [8]. A major challenge for PCa 
treatment is to identify factors controlling tumor growth and 
metastases.
Gene fusions resulting from chromosomal 
rearrangements are known to play an important role in 
tumorigenesis and particularly in PCa [9, 10]. Tomlins et 
al. first described a gene fusion between the regulatory 
element of TMPRSS2 (Transmembrane Protease Serine 
2) gene and ETS (ERG, ETV1, ETV4 or ETV5) genes in 
PCa [11, 12]. TMPRSS2 is a prostate-specific androgen-
regulated gene and its rearrangement leads to an increased 
in the expression of the ETS members in response to the 
androgen. ETS factors are a family of 27 transcription 
factors in mammals and sharing a conserved DNA 
binding domain recognizing 5’-GGAA/T-3’ sequence in 
promoters or regulation regions. ETS transcription factors 
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play an important role in a variety of biological processes, 
including cell proliferation, apoptosis, differentiation, 
angiogenesis and invasiveness [13].
TMPRSS2-ERG gene fusions are one of the most 
predominant genetic events in PCa [10, 12]. More than 
20 TMPRSS2-ERG transcripts were described as result of 
alternative splicing or different recombination mechanisms 
(deletions, insertions or translocations) [10, 14]. The most 
common rearrangement, involving exons 1 of TMPRSS2 
fused to exon 4 of ERG (T1E4), is present in 50% of PCa 
cases [10]. Transcriptomic studies have revealed that ERG 
overexpression in TMPRSS2-ERG-positive PCa cell lines 
leads to the deregulation of key genes for cell migration 
and invasiveness [15–17].
The prognostic implications of TMPRSS2-ERG 
gene fusion in PCa are still unclear. Since its discovery 
in 2005, a large number of studies have been published 
in this field. Some teams found a correlation between the 
presence of this fusion and poor prognosis [18–22], but 
several others report a correlation between the presence of 
this fusion and good prognosis [23–25] or no correlation at 
all [26–28]. Moreover, several studies have demonstrated 
the presence of TMPRSS2-ERG gene fusion, in most 
cases of metastatic PCa [29, 30], and that positive tumors 
have a greater proclivity for developing metastases. On 
the other hand, metastases arising from tumors without 
rearrangement were also found [31]. This discrepancy 
could come from clinical settings, the size of the patients' 
cohort, the difference in sample collection or conservation, 
but also from PCa heterogeneity, fusion variant or ethnical 
differences.
Understanding the mechanisms of bone metastasis 
formation remains a challenge to improve PCa prognosis 
and treatment. This research field is a challenging area 
to explore because of the difficulty in obtaining bone 
metastatic tissues from patients. Animal models then 
become essential tools in exploring the pathogenesis 
of PCa. However very few cell lines reflect tumor 
colonisation, quiescence and subsequent growth in the 
bone following injection in the circulation [32].
In this paper, we used a luciferase expressing cell 
lines derivatives from PC3M, PC3M-luc-C6 (PC3M-luc), 
in a mouse model in order to evaluate the consequences 
of TMPRSS2-ERG fusion on tumor development using 
dynamic monitoring with bioluminescence imaging (BLI). 
New PC3M-luc TMPRSS2-ERG cells stably expressing 
the fusion showed increased migration ability and a 
higher subcutaneous tumor development. Moreover, we 
demonstrated that the presence of TMPRSS2-ERG results 
in a greater number of tumors in bone after intracardiac 
injection. In particular, site-specific patterns of spread are 
influenced by more lesions at hind limbs and spine for 
fusion positive cells. Finally, the TMPRSS2-ERG positive 
tumors harbour more osteoblastic features compared to 
TMPRSS2-ERG negative tumors. Our work provides 
new elements in the knowledge of bone metastasis 
development in PCa.
RESULTS
TMPRSS2-ERG fusion increases migration in 
prostate cancer cell lines
In order to assess the role of TMPRSS2-ERG 
fusion in PCa development, we generated cell lines stably 
overexpressing the fusion using retroviral translocation 
from luciferase expressing cells PC3M-luc. The expression 
of ERG was confirmed by RT-qPCR and immunoblotting 
(Figure 1A). Equivalent luciferase activity for both cell 
lines (PC3M-luc Ctrl and PC3M-luc TMPRSS2-ERG) 
was also checked to eliminate a possible bias in the further 
bioluminescence measurements (Supplementary Figure 1). 
Previously, it has been shown by our team and others that 
no significant cell proliferation changes were observed in 
TMPRSS2-ERG PC3c cells compared with control cells, 
but that TMPRSS2-ERG promotes PC3c cell migration 
[15–17]. To assess this influence in PC3M-luc cell line, 
we performed proliferation and migration assays in the 
xCELLigence system. This instrument monitors cellular 
events in real time without exogenous labelling through 
impedance-based technology [33]. Compared with control 
PC3M-luc cells (Ctrl), TMPRSS2-ERG overexpressing 
PC3M-luc cells exhibit comparable proliferation profiles 
(Figure 1B, right panel). The histograms presented in 
the left panel of Figure 1B show rates of estimated cell 
proliferation similar to the mean slope of the cell growth 
curves for four independent experiments. We then 
evaluated the effect of TMPRSS2-ERG on the migration 
behavior of PC3M-luc prostate cancer cells. As usual, 
we performed the migration assays using foetal bovine 
serum (FBS) as a chemoattractant. Cell migration was 
measured every 15 min for approximatively 24h. We 
found that the TMPRSS2-ERG cells migrate faster than 
the control cells (Figure 1C, left part). The rates of cell 
migration as the means of four independent experiments 
is presented in Figure 1C (right part). Our data confirmed 
previous observations [15–17] and thus demonstrate that 
TMPRSS2-ERG fusion also promotes cell migration in 
PC3M-luc.
TMPRSS2-ERG fusion increases subcutaneous 
tumor growth
The influence of TMPRSS2-ERG fusion on 
subcutaneous tumor growth has already been reported [14, 
34, 35]. In an effort to characterize our new cell lines and to 
evaluate whether TMPRSS2-ERG could influence tumor 
development in an animal model system, we inoculated in 
PC3M-luc control or TMPRSS2-ERG cells the right flank 
of male SCID mice. Tumor development was monitored 
weekly by measuring bioluminescence with IVIS Lumina 
system (Figure 2A and Supplementary Figure 2). The 
growth rate was relatively rapid. Measurable tumors 
began to form 7 days after tumor cell inoculation in all the 
injected mice. At the end of the experiment, the presence 
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Figure 1: TMPRSS2-ERG fusion increases migration in prostate cancer cell line. A. ERG expression in PC3M-luc cell lines. 
Left panel: ERG expression was evaluated by RT-qPCR analysis. Transcript levels were measured following infection of PC3M-luc with 
pLPCX empty vector (Ctrl) or pLPCX TMPRSS2-ERG (TMPRSS2-ERG). Results are normalized with respect to endogenous control 
GAPDH. Immunoblot analysis of ERG protein levels in PC3M-luc Ctrl or TMPRSS2-ERG. Actin was used as a loading control. Primer 
used are avalaible in Supplementary Table 1. B. Left panel: Representative cell index (mean ± standard deviation) as a measure of PC3M-luc 
cell proliferation. Measurements were automatically collected by the RTCA DP analyser every 15 min for up to 3 days (n=2). Red: PC3M-
luc cells infected with pLPCX empty vector (Ctrl); Green: PC3M-luc cells infected with pLPCX TMPRSS2-ERG vector (TMPRSS2-ERG). 
Right panel: Results of the cell proliferation assays represented as slopes (changes in cell index/hour) (n=4) (*= p<0,05). C. Left panel: 
Migration kinetics PC3M-luc cells assessed by continuous monitoring of live cell migration for approximately 24 hours. Red: PC3M-luc 
cells infected with pLPCX empty vector (Ctrl); Green: PC3M-luc cells infected with pLPCX TMPRSS2-ERG vector (TMPRSS2-ERG) 
(n=2). Right panel: Results of the cell migration assays represented as slopes (changes in cell index/hour) (n=4) (*= p<0,05).
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Figure 2: TMPRSS2-ERG fusion increases subcutaneous tumor growth. A. Schematic representation of subcutaneous 
injection experiments. B. Bioluminescence imaging of SCID mice bearing PC3M-luc tumor cells (Ctrl or TMPRSS2-ERG). Left panel: 
Representative pictures on the indicated days after subcutaneous injections. Luminescence is expressed in radiance (p/sec/cm2/sr) and 
represented by the color scale. Right panel: Quantitative analysis of the luciferase expression as a measure of tumor growth at the end of 
the experiment (day 24). Data represents the means of 6 mice in Ctrl group and 5 mice in TMPRSS2-ERG group. * indicated p<0,05. C. 
Picture of excised (up) subcutaneous tumor at day 24 and bioluminescence (BLI, bottom) D. Histologic analysis of subcutaneous tumors 
with anti-ERG antibody (up) and anti-Ki67 antibody (bottom). Magnified insert are shown on the right.
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of TMPRSS2-ERG fusion resulted in a luciferase signal 
six-fold higher than Ctrl cells (Figure 2B). Representative 
time course of tumor development in mice injected with 
Ctrl cells or TMPRSS2-ERG cells is presented in Figure 
2B and Supplementary Figure 2. As can be seen from 
Figure 2C, subcutaneous tumors formed by TMPRSS2-
ERG cells were much more bioluminescent than those 
formed by Ctrl cells. Confirmation of the TMPRSS2-
ERG status was obtained on the tumor sample by 
immunohistochemistry with anti-ERG (Figure 2D). Using 
an anti-Ki67 antibody, we validated the high proliferation 
rate in both tumor groups (Figure 2D).
TMPRSS2-ERG fusion increases dissemination 
in bone mainly in hind limbs and the spine
Given that TMPRSS2-ERG increases both 
the migration in vitro and the subcutaneous tumor 
development, we then tested whether TMPRSS2-ERG 
could be taking part in the bone metastasis formation 
of prostate cancer cells in vivo. In this view, we used an 
experimental metastasis model involving intracardiac 
injections of PC3Mluc tumor cells in SCID mice. This 
approach mimics the haematogenous dissemination of 
cancer cells and allows the examination of the process of 
metastatic colonization at various sites. PC3M-luc Ctrl 
and TMPRSS2-ERG were injected in the left ventricle 
of male SCID mice aged of six weeks (Figure 3A and 
Supplementary Figure 3). The distribution of the cells 
in the whole body 30 minutes after injection, indicating 
successful injection, was apparent for 65% of the 
mice. Only animals with diffuse photon accumulations 
throughout the body were considered for further analysis. 
Then, images were taken twice per week to monitor the 
cell colonization. Mice were euthanized at day 24. These 
experiments were repeated twice and similar results were 
obtained. In total, 10 mice were used to inject PC3M-luc 
Ctrl cells and 9 mice with PC3M-luc TMPRSS2-ERG.
Tumor cell dissemination was rapidly detectable. 
Firstly, we observed a colonization of the nose and 
mandibles (from day 4, with high sensitivity detection). 
Luciferase was later detected in hind limbs and the spine 
(around day 14) (Figure 3B and Supplementary Figure 
3). 24 days after injection 100% of both groups of mice 
had developed bone metastatic foci and whole body 
luminescent was comparable between the two groups 
(Supplementary Figure 3B). Nevertheless, the fusion 
status influences the total number of metastatic sites. 
Animals injected with TMPRSS2-ERG cells had 57% 
more bone metastases compared to the control group 
(Figure 3B) at the end of the experiment.
A more detailed examination revealed that 
TMPRSS2-ERG leads to a higher number of tumors in 
hind limbs and the spine (Figure 3C, 3D). Other sites, such 
as the mandible, nose or ribs were colonized in a similar 
way by both cell lines. Supplementary Figure 4 shows 
the incidence of tumoral lesions per site for each mouse 
considered in our experiment. Macroscopic dissection 
and bioluminescence measurement analysis of metastatic 
sites confirmed luciferase detection corresponding to the 
presence of tumor cells (Figure 3C). Goldner coloration 
of the collected bone samples confirmed bone tumor 
localisation. A histological analysis with antibodies against 
ERG and Ki67 respectively confirmed the TMPRSS2-
ERG status and the high rate of proliferation (Figure 3E 
and Supplementary Figure 5). As expected, the endothelial 
cells of small vessels show positive endogenous ERG and 
are indicated with arrows.
Altogether, these observations show that the fusion 
TMPRSS2-ERG plays an important role tumor cell 
dissemination into the bone, by increasing the incidence 
of bone metastases in hind limbs, in the spine and globally.
Although the clinical PCa bone metastases have 
the predominant osteoblastic phenotype, PCa cell lines 
induced mainly osteolytic lesions [36]. In order to 
characterize bone metastases, we compared the transcript 
levels of some osteoblast-specific markers (OSTERIX 
and RUNX2) and osteoclast-related markers (RANK) 
in PC3M-luc Ctrl or PC3M-luc TMPRSS2-ERG. 
Supplementary Figure 6A shows the expression levels 
in the spine sample of three different mice to account 
for inter-individual variability. These results suggest 
a deregulation of the bone metabolism in favour of an 
osteoblastic phenotype as indicated by the trend towards 
an increase in the expression of osteoblastic markers 
(OSTERIX and RUNX2) and a decrease in the expression 
of the osteoclastic key gene (RANK) (Supplementary 
Figure 6A). Samples were also assessed by histological 
analysis. In samples from mice injected with TMPRSS2-
ERG cells, we noticed an increase in bone matrix as 
highlighted in Supplementary Figure 6B with arrows. 
Finally, we performed immunohistochemistry with an 
anti-RUNX2, which revealed more positive cells in bone 
samples from mice injected with TMPRSS2-ERG cells 
compared with Ctrl cells. To complete this histological 
study, we performed immunohistochemistry experiments 
on mouse bone lesions to detect the Cathepsin K 
expression, which is specific to osteoclasts. As shown in 
Supplementary Figure 6C, Cathepsin K was detected in 
both Ctrl and TMPRSS2:ERG bone lesions in a similar 
manner. This result suggests that, even though the fusion 
expression is associated with osteoblastic feature as 
revealed by the Goldner staining and the osteogenic 
Runx2 gene expression, the TMPRSS2:ERG expression 
does not decrease the osteoclasts number in this model.
TMPRSS2-ERG fusion expression deregulates 
genes involved in cell migration, adhesion and 
skeletal physiology
Since TMPRSS2-ERG fusion product correspond 
to a functional transcription factor, we speculated that its 
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Figure 3: TMPRSS2-ERG fusion increases bone metastasis development. A. Schematic representation of intracardiac 
injection experiments. B. Bioluminescence imaging of SCID mice bearing PC3M-luc tumor cells (Ctrl or TMPRSS2-ERG). Left panel: 
Representative bioluminescence imaging of SCID mice on the indicated times after intracardiac injections. Right panel: Number of tumors 
per mice at indicated days after intracardiac injections. Data represents the mean of 10 mice in Ctrl group and 9 mice in TMPRSS2-ERG 
group. Luminescence is expressed in radiance (p/sec/cm2/sr) and represented by the color scale. * indicated p<0,05. C. Ex vivo detection 
of bone tumor by bioluminescence at day 24. Luminescence is expressed in radiance (p/sec/cm2/sr) and represented by the color scale. D. 
Number of tumors per mice in indicated organ sites at day 24 after intracardiac injections. Data represents the mean of 10 mice in Ctrl group 
and 9 mice in TMPRSS2-ERG group. * indicated p<0,05.
(Continued )
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over-expression in PC3M-luc cells, induces differences 
in their transcriptome. To address the biological 
functions of TMPRSS2-ERG in bone metastasis 
formation, RNA sequencing was employed to compare 
the global gene expression of PC3M-luc TMPRSS2-ERG 
cells versus Ctrl cells (Figure 4, Supplementary Figure 
7 and Supplementary Table 2-6). Overall, the quality of 
the RNA-Seq data and read mapping in our current study 
met the requirements for the bioinformatic analyses. 
Moreover, the expression levels of a set of genes in the 
corresponding clones were validated using qRT-PCR 
(Figure 4E). These data confirmed the RNA-seq results 
and showed the significantly up- and down-expression 
of the genes. In order to explore the gene function 
relevant to the in vitro and in vivo results obtained with 
the PC3M-luc TMPRSS2-ERG clones, GO analysis 
was conducted to group these differentially expressed 
genes into molecular and cellular functions, diseases and 
Figure 3 (Continued ): E. Histologic analysis of bone tumors resulting from intracardiac injection of PC3M-luc Ctrl (left) or PC3M-luc 
TMPRSS2-ERG (right) by Goldner staining (top), with anti-ERG antibody (middle) and anti-Ki67 antibody (bottom). B=Bone, T= Tumor 
cells. Arrows indicate ERG positive vessels cells.
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Figure 4: TMPRSS2-ERG fusion expression deregulates genes involved in cell migration, adhesion and skeletal 
physiology. A. RNA-sequencing analysis. Left panel, Heatmap showing top 20 of differentially expressed genes between PC3M-luc 
Ctrl and TMPRSS2-ERG cells. A technical duplicate was analysed for each sample (#1 and #2). The heatmap scale shows the range of 
expression level, whereby positive (red) and negative (blue) values correspond, respectively, to a higher and a lower expression. Right 
panel, pie chart showing the percentage of significatively (p value <0.05) up and downregulated genes in TMPRSS2-ERG cells versus 
control cells. B. Examples of RNA-Seq peaks (UCSC traks). C. Top 20 of significatively deregulated genes. 
(Continued )
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physiological system development and function (Figure 
4E and supplementary Figure 7). In brief, GO analysis 
of genes showed that these genes are involved in 
cellular growth and proliferation, cell movement, tissue 
development, skeletal and muscular system development 
(Figure 4 and Supplementary Figure 7 and Table 2-5). 
Most of the identified genes are involved in cancer and 
metastasis (Supplementary Table 2). More importantly, 
a large part of the deregulated genes are in the GO 
category “Connective tissues” (Supplementary Table 5) 
and involved in “Differentiation of bone cells” such as 
CCL2, INHBA, ITGA5, NOS3, SIGLEC15, WNT7B or in 
“Development of connective tissue” such as CXCL11, 
ICAM1, INHBA, ITGA5, ITGB8, MMP13, PECAM1, 
PLA2G4A, WNT7A, WNT7B. Interestingly, some 
genes belong to the “Homing of cell” GO categories (20 
Figure 4 (Continued): D. Validation of expression changes observed in RNA-Seq by q-PCR. Results are normalized with respect to 
endogenous control GAPDH. E. Ingenuity pathway analysis (“Diseases and Disorders” and “Molecular and Cellular Function”) of the 
differentially expressed genes. The x axis represents the number of molecules per categories.
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genes), others to “Migration of cells” (60 genes) or to 
the “Extravasation” (6 genes) which is an important step 
of metastatic mechanism (Supplementary Table 3 and 
4). In summary, over-expression of TMPRSS2-ERG was 
sufficient to modulate transcription of genes involved 
in cell migration/adhesion and mechanisms known to 
be associated with bone physiology. In particular, de-
regulation of mRNAs whose gene products are involved 
in cancer and metastasis was observed.
DISCUSSION
PCa is a global public health problem, and in 
particular bone metastasis development which is 
responsible for main morbidity. Bone lesions are difficult 
to cure and are often synonym of fatal outcome. Therefore, 
there is an urgent need to develop therapeutic strategies 
that target advanced PCa and its interactions with the bone. 
A prerequisite for the development of new therapeuties 
is to improve our understanding of the fundamental 
mechanisms that regulate the metastatic process, including 
dormancy and growth of tumor cells in the bone. Previous 
studies failed to reach clear conclusions about the role of 
TMPRSS2-ERG in bone metastases. Finding good and 
relevant models is a real challenge in prostate cancer 
research. In this view, we developed PC3M-luc cells lines 
stably overexpressing the fusion TMPRSS2-ERG.
In this study, in vitro experiments showed that the 
TMPRSS2-ERG fusion increases cell migration. This 
result is in agreement with previous studies obtained 
with PC3 and other cell lines [15–17], confirming the 
validity of our PC3M-luc model. By way of subcutaneous 
injection, we clearly demonstrated that TMPRSS2-ERG 
overexpression leads to higher bioluminescent signal, 
which reflects the presence of more tumor cells. This 
last data, in addition to be in line with in vitro migration 
results, suggests that the fusion may be involved in 
microenvironment interactions enhancing tumor growth 
in vivo. Several previous studies have demonstrated 
the presence of the TMPRSS2-ERG gene fusion in 
the majority of metastatic PCa [29, 30, 37] and that the 
positive foci have a greater proclivity for metastases [29]. 
Nevertheless, others reported that the metastases may also 
arise from the tumor without ERG rearrangement [31]. 
Animal models are very useful tools to better understand 
mechanisms involved in PCa metastases. Here, we used 
intracardiac injections to evaluate whether the TMPRSS2-
ERG fusion plays a role in tumor propagation to the bone. 
This technology imitates the propagation of cancer cells in 
blood circulation and is the method of choice to follow the 
homing of PCa cells in various tissues. Our work showed 
that PC3M-luc cells, expressing TMPRSS2-ERG, show 
a higher rate of colonization in bone compared to Ctrl 
cells. Crucially, this indicates a major involvement of the 
fusion in bone metastases, and therefore suggests that the 
TMPRSS2-ERG fusion may play a role in bone tropism 
of PCa tumor cells.
Interestingly, anatomical sites presenting increased 
tumors are hind limbs and spine, which are two of the most 
affected tissues in human pathology [38, 39]. Metastatic 
PCa cells in the spine and hind limbs provide some of 
the worst symptoms of the disorder due to pathological 
fracture or epidural spinal cord compression [40]. The 
fact that these two bone lesion localisations reflect human 
pathologies demonstrates that the intracardiac injection of 
PC3M-luc cells are a good and relevant model to study 
PCa pathology.
It was suggested that osteotropism of PCa cells is a 
consequence of the development of a bone-like behavior. 
This theory, called osteomimicry, is the ability of cancer 
cells to express genes previously highly restricted to 
bone cells during and after metastasis in order to adapt 
and grow in the bone environment [3, 4, 41, 42]. We 
have shown here that TMPRSS2-ERG influences the 
transcription of bone master genes, suggesting that the 
fusion TMPRSS2-ERG may be a driver of osteomimicry. 
Moreover, TMPRSS2-ERG seems to destabilize the 
bone metabolism by increasing the transcript level of 
two osteoblastic genes, being RUNX2 and OSTERIX 
[43, 44], and decreasing the expression of an osteoclastic 
gene, RANK [45]. However, using immunohistochemistry 
experiments on mouse bone lesions to detect Cathepsin K 
expression, which is specific to osteoclasts, we revealed 
that, compared to Ctrl tissue, osteoclast number was 
not decresed in TMPRSS2-ERG bone lesions. This 
result suggests that, even though the fusion expression 
is associated with osteoblastic feature as revealed by 
the Goldner staining and the osteogenic RUNX2 gene 
expression (Supplementary Figure 6A-6B), the TMPRSS2- 
ERG expression does not decrease the osteoclast number 
in this model. In line with this results, Li et al. showed 
that osteoclastogenesis and bone resorption are mutually 
essential for prostate cancer establishment in the bone 
microenvironment [46]. Moreover, they demonstrated that 
CCL2 (Monocyte chemoattractant protein 1) increased 
osteoclastic bone resorption to facilitate prostate cancer 
tumor growth in bone. Interestingly, as revealed by RNA-
Seq analysis, CCL2 gene is upregulated in PC3M-luc 
TMPRSS2-ERG clone compared with the Ctrl clones. In 
this respect, the TMPRSS2-ERG fusion seems to favour 
the development of osteoblastic lesions. Since ERG is a 
transcriptional factor which could act as an activator of 
transcription but also as a transcriptional repressor [47, 
48], the effect of TMPRSS2-ERG on RUNX2, OSTERIX, 
RANK and CCL2 expression, suggests that these genes 
could be potential ERG targets. Further studies should be 
performed to establish if these genes are directly bound 
by ERG factor.
Our results suggest that the TMPRSS2-ERG fusion 
may be a target to inhibit bone metastases. Further to our 
results, it would be interesting to assess if treatment with 
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ERG inhibitors could reduce the number of developed 
bone metastases. An inhibitor such as DB1255, which 
specifically targets the ERG DNA recognition sites [49] 
or ERG-specific siRNA [34] could be potential anti-
metastatic compounds. Positive results could open new 
promising therapeutic possibilities to treat prostate cancer 
bone metastases.
In summary, our findings show that the TMPRSS2-
ERG fusion play a role in PCa bone metastasis formation.
MATERIALS AND METHODS
Cell lines and retroviral infection
PC3M-luc-C6 cell line was purchased from 
Caliper (Perkin Elmer). PC3M-luc are derived from 
PC3 cell line, originally isolated from a bone metastasis 
of human prostatic adenocarcinoma [50] [51]. To 
produce highly metastatic cells, they were obtained after 
multiple selection cycles of orthotopic injection, after 
the subsequent isolation of metastatic cells and after 
orthotopic reinjection(s) [52].
Cells were grown in MEM (Life Technologies) 
medium containing 10% foetal bovine serum and 
glutamine (2mM final) under standard culture conditions. 
Retroviral infections to stably expressed the TMPRSS2-
ERG fusion were realized as already described [15]. 
Briefly, 293 GP cells were transfected with pLPCX 
retroviral vectors. Supernatant were then collected and 
used to infect PC3M-luc-C6 target cells. For further 
experiments, we used a pool of several clones obtained by 
puromycine selection without clonal selection.
Cell proliferation and migration assays
To evaluate PCa cell proliferation, PC3M-luc-C6 
cells infected with pLPCX empty vector (Ctrl) or pLPCX 
TMPRSS2-ERG were seeded into the xCELLigence 
E-plate 16 (Roche) (10000 cells/well) according to the 
manufacturer’s instructions. Measurements were collected 
by the RTCA DP analyser for up to 3 days. Four replicate 
measurements per condition were obtained. The data 
were analysed with the provided RTCA software. To 
examine PCa cell migration, PC3M-luc-C6 cells Ctrl 
or TMPRSS2-ERG were seeded 24 h post-transfection 
into the xCELLigence CIM-plate 16 (Roche). Briefly, 
a 165-μl volume of fresh medium containing 10% FBS 
(chemoattractant) or with serum-free medium (control) 
was added to the lower chambers of the CIM-plate 16. 
The upper chambers were filled with serum-free medium 
(30 μl/well) and the plate was incubated at 37°C in 5% 
CO2 for 1 h. Cells (60000 cells/well) were then added to 
each well of the upper chamber. After 30 min, the CIM 
plate was assembled onto the RTCA DP analyser and cell 
migration was assessed at 20 h at 37°C in 5% CO2. Four 
replicate measurements per condition were obtained. The 
data were analysed with the provided RTCA software.
Animal tumor models
All animal experiments were approved by the 
local ethics committee (CSTMT-042). Six to eight 
week old male SCID mice were used. PC3M-luc-C6 
(3.106) suspended in 200μl of PBS were implanted 
subcutaneously in the flank region of SCID mice. For 
intracardiac injections, mice were maintained under 
isoflurane anaesthesia during injection procedure. PC3M-
luc-C6 (106) were suspended in 200μl of PBS and were 
injected into the left ventricle using a29-G needle. 
Bioluminescence imaging was performed 30 minutes after 
intracardiac injection. Only animals with diffuse photon 
accumulations throughout the body of the animal were 
considered for further analysis. Animals were monitored 
for 4 weeks after injection.
Bioluminescence imaging
Mice were injected subcutaneously with D-luciferin 
(15 mg/ml in sterile PBS, Perkin Elmer) 10 min before 
being imaged. The mice were anesthetized with 2% 
isoflurane and were imaged in dorsal and/or ventral 
position using an IVIS Lumina System (Caliper) to 
monitor the tumor growth and metastatic dissemination. 
A bioluminescent image was obtained with a 12.5 cm 
field of view, a binning factor of 8, and a 1/f stop-and-
open filter. Regions of interest were defined manually, 
and signal intensities were calculated with Living Image 
software (Caliper) and expressed as photons per second. 
Background photon flux was defined from a region of 
interest drawn over a control.
RNA-sequencing
The total RNA was purified by RNeasy kit (Qiagen) 
from two distinct infections (#1 and #2) of PC3M-luc 
ctrl and TMPRSS2-ERG was used to perform RNA 
sequencing. Construction of the library was done with 
1μg of total RNA and Tru-seq stranded mRNA sample 
preparation kit (Illumina) according manufacturer’s 
instructions. The reads were aligned to the hg19 reference 
assembly using RNA-STAR [53]. Counting reads 
were mapped to genes with HTSeq-count under the 
union-intersection mode on refSeq hg19 transcriptome 
annotations. PCR duplicates were filtered. A gene was 
considered differentially expressed at transcript level when 
unpaired t-test P-value <0.05.
Statistical analysis
All data are expressed as mean ± SEM. Statistical 
significance was tested for using an unpaired Student’s 
Oncotarget11838www.impactjournals.com/oncotarget
t-test. p < 0.05 was considered to be significant and is 
indicated as *.
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